Alpine Immune Sciences’ (ALPN) Hold Rating Reiterated at TD Cowen

TD Cowen restated their hold rating on shares of Alpine Immune Sciences (NASDAQ:ALPN) in a research note published on Tuesday morning, Benzinga reports.

Several other equities analysts also recently weighed in on ALPN. Morgan Stanley reaffirmed an equal weight rating and issued a $65.00 target price (up from $47.00) on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. Leerink Partnrs downgraded Alpine Immune Sciences from an outperform rating to a market perform rating in a research report on Thursday, April 11th. Wedbush downgraded Alpine Immune Sciences from an outperform rating to a neutral rating in a research report on Thursday, April 11th. Guggenheim started coverage on Alpine Immune Sciences in a research report on Tuesday, April 9th. They set a buy rating and a $55.00 price objective for the company. Finally, Wolfe Research reissued a peer perform rating on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. Eight investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of Hold and a consensus price target of $50.33.

Alpine Immune Sciences Price Performance

NASDAQ ALPN opened at $64.50 on Tuesday. The company has a market cap of $4.23 billion, a P/E ratio of -100.78 and a beta of 1.14. The stock has a 50-day moving average of $37.92 and a two-hundred day moving average of $23.86. Alpine Immune Sciences has a 1-year low of $6.71 and a 1-year high of $64.57.

Alpine Immune Sciences (NASDAQ:ALPN) last released its earnings results on Monday, March 18th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.47. The company had revenue of $30.85 million during the quarter, compared to the consensus estimate of $6.90 million. Alpine Immune Sciences had a negative return on equity of 15.54% and a negative net margin of 54.66%. On average, analysts anticipate that Alpine Immune Sciences will post -1.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Alpine Immune Sciences

Institutional investors have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC lifted its stake in Alpine Immune Sciences by 745.5% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,312 shares during the last quarter. Royal Bank of Canada lifted its stake in Alpine Immune Sciences by 99.1% during the second quarter. Royal Bank of Canada now owns 2,642 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 1,315 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in Alpine Immune Sciences during the fourth quarter worth approximately $58,000. AJOVista LLC purchased a new stake in Alpine Immune Sciences during the fourth quarter worth approximately $64,000. Finally, Public Employees Retirement System of Ohio purchased a new stake in Alpine Immune Sciences in the third quarter valued at approximately $35,000. Hedge funds and other institutional investors own 75.17% of the company’s stock.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.